Articles tagged with Metastasis
A subgroup analysis from a phase III clinical trial found that eribulin demonstrated a greater potential benefit in overall survival compared to capecitabine for women with previously treated metastatic breast cancer. Specifically, patients with multiple organs involved, those who had not received chemotherapy for six months or longer,...
Researchers at Uni Basel have discovered Sox4 as a key player in cancer metastasis, triggering the epithelial-mesenchymal transition (EMT) process. The study found that Sox4 promotes the expression of genes involved in EMT and metastasis, leading to changes in gene expression and cell behavior.
A new hybrid molecular imaging system combines positron emission tomography and magnetic resonance to detect recurrent prostate cancer. The study reveals that PET/MR finds more areas of metastases than PET/CT, making it a viable alternative for restaging patients with metastatic prostate cancer.
Researchers have developed a novel imaging agent, Tc-99m MIP-1404, which binds to PSMA enzyme in prostate cancer cells, enabling detection of metastases. The agent shows promise in detecting lesions more accurately than standard bone imaging.
Researchers at University of South Florida found a combination of nontoxic therapies prolonged survival time by 78% in mice with metastatic cancer. The treatment combined ketogenic diet and hyperbaric oxygen therapy, both non-toxic to healthy tissues while damaging cancer cells.
Scientists developed a potential new drug that destroys cancer cells while preventing their spread to other sites in the body. The compound was tested in laboratory mice and showed promising results.
The EORTC BOS 2 trial aims to improve outcomes for patients with resectable liver metastases from colorectal cancer by testing the efficacy of bevacizumab or panitumumab added to standard peri-operative FOLFOX 4 chemotherapy. The trial plans to accrue 360 patients in 50 sites across ten countries.
Researchers at Berkeley Lab identified the microenvironment surrounding microvasculature as a niche where dormant breast tumor cells reside. The study reveals that stable microvasculature suppresses growth and creates a dormant niche, while sprouting neovasculature sparks micrometastatic outgrowth.
A genetic rogue element known as chimeric transcript LCT13 is linked to the silencing of a tumor suppressor gene TFPI-2, promoting cancer invasion and metastasis. The study suggests that 'junk DNA' can interfere with normal cell function, providing new insights into cancer progression.
Researchers have discovered that targeting regulatory T cells can help eliminate cancer cells, while a new fluorescence labeling method enables the visualization of microRNAs in tissue sections. Additionally, studies suggest that malnourishment exacerbates Giardia infection in mice, leading to severe gastrointestinal problems and growt...
Researchers have identified a five-amino acid fragment of prosaposin that significantly reduces metastatic spread in mouse models of prostate, breast and lung cancer. The findings suggest a potential new approach to blocking metastasis in various cancers.
Researchers at MU College of Veterinary Medicine have created radioactive nanoparticles that target lymphoma tumor cells, a crucial step toward treating metastasized cancers. The nanoparticles, made with lutetium and gold shells, can deliver radiation to tumors without harming healthy cells.
Researchers found that a tumor-activated protein, VEGF-C, activates integrin α4β1 on lymphatic vessels in lymph node tissues, making them more attractive to metastatic tumor cells. This highlights the way tumors can have long-range effects on other parts of the body, impacting tumor metastasis or growth.
Researchers at Stanford University School of Medicine developed a new technique to visualize cell interactions in living mice, pinpointing metastatic cancer cells' locations after breaking off from initial tumor sites. The method uses light-emitting proteins and has potential applications in studying various cell interactions.
A recent study by Henry Ford Health reveals that prostate cancer patients with metastasis are more likely to die after weekend emergency department visits compared to weekdays. The study found that these patients have a 23% increased likelihood of death after weekend visits, despite being older and healthier on average.
Researchers have discovered that breast cancer patients with dense breasts are more likely to develop aggressive tumors. A protein called DDR2 plays a key role in this process, facilitating the spread of cancer cells by activating a multistep pathway.
Scientists at Weill Cornell Medicine have discovered two key proteins that work to block cancer's spread by generating a microenvironment that prevents cancer cells from settling and growing in distant organs. The study suggests that therapeutic proteins could offer a new treatment strategy for metastatic cancer.
Cancer cells exhibit unique physical properties as they metastasize, including increased deformability and reduced oxygen consumption. This study provides new insights into the dynamics of cancer cell behavior, suggesting that these traits enable them to spread through the body.
Researchers have developed a new way to learn how good cells go bad by studying the mechanical and biochemical behavior of cells simultaneously. This technology combines atomic force microscopy and nuclear magnetic resonance, allowing for detailed insights into disease processes.
Researchers discovered metastasis stem cells in the blood of breast cancer patients, characterized by specific surface molecules CD44, CD47, and MET. These cells are associated with a poorer prognosis and may serve as a promising biomarker for disease progression.
Research finds that palliative radiotherapy significantly improves the quality of life for elderly patients with painful bone metastases. The treatment, which involves a single fraction of radiotherapy, has been shown to be effective in all age groups, including those over 75, despite some variability in response.
A new therapy uses radioactive Listeria bacteria to selectively infect tumor cells and deliver radioisotopes, dramatically decreasing the number of metastases in a mouse model of highly aggressive pancreatic cancer. The treatment also showed promise in reducing metastases by 90% in mice with metastatic pancreatic cancer.
Dr. Susan E. Clare's research aims to deliver chemotherapy directly to brain metastases using immune cells and nanoparticles, targeting HER2 positive and triple negative breast cancers. The system uses nanoshells coated with gold to release drugs at will in the appropriate spot in the brain.
Researchers found that combining CT imaging findings with baseline serum lactate dehydrogenase levels can accurately predict patient survival. Patients with low baseline serum LDH and evidence of tumor devascularization on their initial post-therapy CT scans are likely to have a favorable response to therapy.
Researchers found that HIF1 and HIF2 are overexpressed in melanoma tumors, promoting the spread of cancer through the lymphatic system. Suppressing these transcription factors reduced the rate of metastasis in mouse models.
High levels of kisspeptins in aggressive breast cancers increase tumor grade and metastatic potential, according to Western University research. The study suggests that estrogen receptor status may play a role in kisspeptin's unusual behavior, making it a potential diagnostic biomarker for more aggressive breast cancer.
LSUHSC researchers identify LKB1 and Nischarin as a functional duo that regulate breast cancer cell migration and tumor growth. The study provides insight into the molecular mechanisms of tumor suppressor genes.
A team of researchers at Baylor College of Medicine has identified a signature of biomarkers that identifies circulating breast tumor cells destined to seed the brain with deadly cancer. The study shows limitations of current platforms used to identify cancer in this way, but also offers new hope for diagnosis and treatment.
Research reveals Six2 homeoprotein promotes detachment of breast cancer cells from tissues, enabling their survival through the bloodstream and colonization at distant sites. Higher Six2 expression in human breast cancer tissues is associated with aggressive metastasis.
A novel protein governing metastasis and chemoresistance in pediatric osteosarcoma has been discovered using K9 osteosarcoma samples. The IGF2BP1 protein's overexpression is linked to aggressive disease progression, offering a potential target for treatment.
Research at the University of Colorado Anschutz Medical Campus reveals that hsa-miR-146a is overexpressed in most metastatic bladder cancer tumors. This tiny miRNA molecule plays a crucial role in making bladder cancer more aggressive.
A Phase III clinical trial found that adding cetuximab to chemotherapy enables previously inoperable patients to undergo surgery, tripling the rates of successful surgery for liver metastasis. The combination also extends median overall survival by 10 months compared to chemotherapy alone.
Researchers have developed a non-invasive test for metastatic prostate cancer using whole-genome analysis of plasma DNA, which identifies abnormal copy numbers of specific sequences. This breakthrough could aid personalized therapy and target treatment for castration-resistant prostate cancer.
Researchers at Moffitt Cancer Center found that microRNA-155 overexpression promotes new blood vessel growth, tumor inflammation, and metastasis in breast cancer. Controlling miR-155 expression could inhibit malignant growth, providing a new avenue of treatment.
The CTC-iChip system rapidly produces a purified solution of tumor cells for pathological and molecular analysis. This technology enables the analysis of single metastatic cells, providing insights into cancer evolution and metastasis.
A CU Cancer Center study reveals that the transcription factor SPDEF regulates E-Cadherin production, inhibiting prostate cancer metastasis. The researchers found that increasing or decreasing SPDEF levels directly affects E-Cadherin expression, making it a crucial factor in preventing cancer spread.
Researchers at Sanford-Burnham Medical Research Institute discovered that the enzyme PKCζ acts as a tumor suppressor in both mice and humans, controlling cell growth and metastasis. Restoring PKCζ levels may provide a novel therapeutic target for treating prostate cancer.
Researchers at UNC have found that protein palladin enhances cancer-associated fibroblasts' ability to break down barriers and create pathways for tumors to spread. This discovery could lead to new treatments and screening options for pancreatic cancers.
Researchers have developed a multi-stage, multi-orifice flow fractionation system to detect and separate circulating tumor cells (CTCs) from blood with high efficiency, improving separation efficiency to 98.9%. The device, called MS-MOFF, employs hydrodynamic sorting and can collect viable CTCs after sorting.
A study by the ZEUS group found no significant difference in the incidence of bone metastases between patients receiving zoledronic acid and those on standard treatment. The 50-month study suggested that zoledronic acid may not be effective in preventing hormone therapy-induced bone loss in high-risk prostate cancer patients.
A large multicentre study found that small kidney tumours can have an aggressive potential and should be treated. The study included 2197 patients with RCC of 4 cm or smaller and showed that the risk of nodal disease or distant metastasis increased significantly with rising tumour diameter.
A study published in Science Signaling identified a critical protein role in the spread of melanoma to the lungs. Researchers found that inhibiting the adenosine diphosphate ribosylation factor 6 (ARF6) protein reduces melanoma metastasis.
Researchers at VCU Massey Cancer Center have developed a novel immunotherapy that could work like a vaccine against metastatic cancers. The therapy, called Flagrp-170, uses a molecule engineered to stimulate the immune system and attack cancer cells, with promising results in animal models.
Researchers found that patients with metastatic gastric cancer who underwent both surgery and radiation had better survival rates than those receiving one or no treatment. Radiation therapy also showed promise in reducing symptoms such as pain, obstruction, and bleeding from gastric tumors.
A recent study found a small but statistically significant increase in the incidence of advanced breast cancer among young women aged 25-39 years, without a corresponding increase in older women. This trend is concerning due to the poor prognosis and lower survival rates associated with younger patients.
Researchers at UH Cancer Center identify RSK2 protein as key player in cancer cell migration and metastasis. The discovery may lead to selective treatments targeting specific tumor types, improving treatment outcomes.
A meta-analysis found that increased fascin-1 is associated with increased risk of mortality in breast, colorectal, and oesophageal carcinomas. Fascin-1 was also linked to disease progression and metastasis in some cases, but not others.
Scientists have generated molecules that inhibit tumour cell adhesion to other cells, halting both tumour growth and liver metastasis. The breakthrough could lead to new treatments for colon cancer and its related death toll.
Researchers found that IQGAP1, a molecule controlling cell shape and movement, can suppress the growth of liver tumors when active in surrounding cells. The study provides new insight into cancer metastasis and points to potential therapeutic targets for preventing or treating liver metastases.
Researchers identified miR-7 as a metastasis suppressor that suppressed cancer stem-like cells' ability to metastasize to the brain. The miR-7/KLF4 axis played a critical role in cancer stem-like cell brain metastasis, suggesting its potential as a diagnostic or therapeutic target for predicting or treating brain metastases.
Researchers discovered that long non-coding RNA MALAT1 regulates genes involved in metastasis, leading to impaired mobility and tumor growth. By silencing MALAT1, the team found reduced metastasis formation in mice, opening a promising approach for lung cancer treatment.
A genetically reprogrammed Herpes simplex virus has been engineered to target and kill cancer cells expressing the HER-2 oncogene, specifically breast and ovarian cancer metastases. This breakthrough oncolytic herpesvirus has shown promising results in treating experimental metastasis, holding promise for a novel type of cancer treatment.
Researchers associate epithelial-mesenchymal transition (EMT) with breast cancer disease progression and treatment response. EMT was detected in breast cancer patient samples and found to oscillate between epithelial and mesenchymal states, influencing tumor spread and invasiveness.
Researchers at Georgia State University have identified a new target to stop cancer's spread, targeting the interaction between two proteins in cells. Disrupting this interaction inhibits metastasis and has implications for treating various diseases.
GATA3 acts downstream to activate microRNA29b, which stops tumor cells from spreading by inhibiting genes involved in metastasis. The absence of GATA3 allows cancerous cells to break free and induce inflammation and new blood vessel formation.
Researchers at BRIC, University of Copenhagen, have found that blocking the enzyme Lysyl Oxidase (LOX) can significantly decrease metastasis in breast cancer models. This breakthrough suggests a new approach to prevent tumour microenvironment scarring and enhance patient outcomes.
Researchers discovered stable epigenetic marks across all metastatic tumors in each patient, defying the idea that these marks vary greatly within individuals. These consistent methylation changes appear to represent driver changes critical to cancer development and could be targets for treatment.
Breast cancer cells use pro-inflammatory signaling molecules to adhere to blood vessel surfaces, promoting metastasis. The Cornell researchers found that these cells are unable to interact with selectins, a key step in the process, and that inflammatory molecules enable them to adhere.
A University of Colorado Cancer Center study found that SPARC acts as an anti-inflammatory drug, reducing tumor growth and metastasis in bladder cancer. The protein is produced by healthy tissue to mute tumors, but aggressive cancers suppress its production, leading to faster disease progression.
The hepatitis B virus X protein (HBx) represses microRNA-148a, leading to increased levels of the oncogenic protein HPIP and subsequent oncogenic transformation in liver cancer. This study demonstrates a cancer-associated virus promoting carcinogenesis through direct manipulation of a microRNA.